Skip to search formSkip to main contentSkip to account menu

TAS-116

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

BenzamidesPyrazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
Despite the effectiveness of imatinib mesylate (IM), most gastrointestinal stromal tumours (GISTs) develop IM resistance, mainly… 
2018
2018
TAS-116. Second-generation HSP90-alpha/beta inhibitor, Cancer therapy
2017
2017
First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in advanced solid tumors.
2546Background: TAS-116 is an oral non-ansamycin, non-purine, and non-resorcinol highly selective inhibitor of HSP90α/β. The… 
2017
2017
Effects of HSP90 inhibitor TAS-116 on the inflammasome activation in ARPE-19 cells
2014
2014
592 TAS-116, a highly selective inhibitor of heat shock protein 90a/β, inhibits tumor growth in biliary tract cancer mouse models
2013
2013
Antitumor Activities Of An Oral Selective HSP90α/β Inhibitor, TAS-116, In Combination With Bortezomib In Multiple Myeloma
Heat-shock protein 90 (HSP90) is a molecular chaperone considered to be attractive therapeutic target in many cancers, including… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)